Oncolytic adenoviruses: A thorny path to glioma cure

I. V. Ulasov*, A. V. Borovjagin, B. A. Schroeder, A. Y. Baryshnikov

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Glioblastoma Multiforme (GBM) is a rapidly progressing brain tumor. Despite the relatively low percentage of cancer patients with glioma diagnoses, recent statistics indicate that the number of glioma patients may have increased over the past decade. Current therapeutic options for glioma patients include tumor resection, chemotherapy, and concomitant radiation therapy with an average survival of approximately 16 months. The rapid progression of gliomas has spurred the development of novel treatment options, such as cancer gene therapy and oncolytic virotherapy. Preclinical testing of oncolytic adenoviruses using glioma models revealed both positive and negative sides of the virotherapy approach. Here we present a detailed overview of the glioma virotherapy field and discuss auxiliary therapeutic strategies with the potential for augmenting clinical efficacy of GBM virotherapy treatment.

Original languageEnglish (US)
Pages (from-to)214-226
Number of pages13
JournalGenes and Diseases
Issue number2
StatePublished - Dec 1 2014


  • Adenovirus
  • Brain tumor
  • Glioma
  • Self-replicated vector
  • Stem cells

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics(clinical)
  • Cell Biology

Fingerprint Dive into the research topics of 'Oncolytic adenoviruses: A thorny path to glioma cure'. Together they form a unique fingerprint.

Cite this